Trial Outcomes & Findings for Relation Between NLR and IMR in STEMI Patients (NCT NCT02828137)
NCT ID: NCT02828137
Last Updated: 2016-08-22
Results Overview
IMR in low NLR group : 21.94 ± 12.87 IMR in intermediate NLR group : 23.22 ± 12.73 IMR in high NLR group : 32.95 ± 20.60
Recruitment status
COMPLETED
Target enrollment
123 participants
Primary outcome timeframe
3 months
Results posted on
2016-08-22
Participant Flow
Participant milestones
| Measure |
Low NLR Group
Neutrophil-to-Lymphocyte (NLR) Ratio \< 1.78
|
Intermediate NLR Group
1.78 \< Neutrophil-to-Lymphocyte (NLR) Ratio \< 3.90
|
High NLR Group
Neutrophil-to-Lymphocyte (NLR) Ratio \> 3.90
|
|---|---|---|---|
|
Overall Study
STARTED
|
41
|
41
|
41
|
|
Overall Study
COMPLETED
|
41
|
41
|
41
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Relation Between NLR and IMR in STEMI Patients
Baseline characteristics by cohort
| Measure |
Low NLR Group
n=41 Participants
Neutrophil-to-Lymphocyte (NLR) Ratio \< 1.78
|
Intermediate NLR Group
n=41 Participants
1.78 \< Neutrophil-to-Lymphocyte (NLR) Ratio \< 3.90
|
High NLR Group
n=41 Participants
Neutrophil-to-Lymphocyte (NLR) Ratio \> 3.90
|
Total
n=123 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
34 Participants
n=5 Participants
|
32 Participants
n=7 Participants
|
30 Participants
n=5 Participants
|
96 Participants
n=4 Participants
|
|
Age, Categorical
>=65 years
|
7 Participants
n=5 Participants
|
9 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
27 Participants
n=4 Participants
|
|
Age, Continuous
|
55 YEARS
STANDARD_DEVIATION 10 • n=5 Participants
|
55 YEARS
STANDARD_DEVIATION 11 • n=7 Participants
|
58 YEARS
STANDARD_DEVIATION 12 • n=5 Participants
|
57 YEARS
STANDARD_DEVIATION 12 • n=4 Participants
|
|
Sex: Female, Male
Female
|
6 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
13 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
35 Participants
n=5 Participants
|
37 Participants
n=7 Participants
|
38 Participants
n=5 Participants
|
110 Participants
n=4 Participants
|
|
Region of Enrollment
Korea, Republic of
|
41 participants
n=5 Participants
|
41 participants
n=7 Participants
|
41 participants
n=5 Participants
|
123 participants
n=4 Participants
|
PRIMARY outcome
Timeframe: 3 monthsIMR in low NLR group : 21.94 ± 12.87 IMR in intermediate NLR group : 23.22 ± 12.73 IMR in high NLR group : 32.95 ± 20.60
Outcome measures
| Measure |
Low NLR Group
n=41 Participants
Neutrophil-to-Lymphocyte (NLR) Ratio \< 1.78 IMR 21.94 ± 12.87
|
Intermediate NLR Group
n=41 Participants
1.78 \< Neutrophil-to-Lymphocyte (NLR) Ratio \< 3.90 IMR 23.22 ± 12.73
|
High NLR Group
n=41 Participants
Neutrophil-to-Lymphocyte (NLR) Ratio \> 3.90 IMR 32.95 ± 20.60
|
|---|---|---|---|
|
Index of Microcirculatory Resistance
|
21.94 IMR
Standard Deviation 12.87
|
23.22 IMR
Standard Deviation 12.73
|
32.95 IMR
Standard Deviation 20.60
|
Adverse Events
Low NLR Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Intermediate NLR Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
High NLR Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place